Follow-The-Filings

Security

GRCE

Grace Therapeutics Inc. · COM

Equity holders as of 2026 Q1 (each manager’s latest book)

4 owners 1 new max 0.0% (Vanguard Group Inc.)

grid → activity →
owners 4
max % 0.0%
tracked value $3M
qoq N 1 A 3

holders

sorted by % of portfolio · long equity only

manager % port activity shares value history
Vanguard Group Inc. 2025 Q4 stale 0.0% Add 0.00 pp 423,981 $1M hist
Renaissance Technologies LLC 2026 Q1 0.0% Add 0.00 pp 243,910 $1M hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% Add 0.00 pp 98,742 $457 hist
Marshall Wace - Marshall Wace, LLP 2026 Q1 0.0% New 0.0% 91,416 $423 hist

4 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025 FY2026
Revenue — — — —
Gross profit — — — —
Gross margin — — — —
Net income -$42.43M -$12.85M -$9.57M -$7.79M
Net margin — — — —

Balance sheet

Metric FY2023 FY2024 FY2025 FY2026
Total current assets $29.29M $24.01M $22.71M $17.38M
Total non-current assets * $49.83M $49.29M $49.28M $49.27M
Total assets $79.12M $73.3M $71.99M $66.65M
Total current liabilities $3.41M $1.68M $1.93M $2.15M
Total non-current liabilities * $7.76M $9.87M $3.45M $612,000
Total equity $67.96M $61.74M $66.61M $63.9M

Cash flow

Metric FY2023 FY2024 FY2025 FY2026
Cash from operations -$15.91M -$12.33M -$14.9M -$8.87M
Cash from investing $13.15M $104,000 $0.00 $0.00
Cash from financing $304,000 $7.36M $14.03M $3.71M
Net change in cash -$2.46M -$4.87M -$872,000 -$5.16M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders